case based panel discussion - adv non squamous nsclc, low pd-l1 no mutation - best systemic therapy?
Published 5 years ago • 97 plays • Length 12:59Download video MP4
Download video MP3
Similar videos
-
9:07
case based panel discussion - adv non squamous nsclc, high pd-l1, no mutation - optimal 1st line?
-
11:09
case based panel discussion - fit patient adv squamous nsclc low tumor pd-l1
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
9:21
case based panel discussions - metastatic squamous nsclc low tumor pd-l1 frail patient - treatment?
-
6:30
stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
8:18
case based panel discussion - egfr and high pdl-1, choosing targeted therapy or immunotherapy
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
5:17
immunotherapy in stage iii nsclc - case based panel discussion
-
5:39
non-bulky nsclc 2b disease: the role of chemoimmunotherapy - case based panel discussion
-
8:17
case based panel discussion - rapid progression adenocarcinoma high pd-l1 - how do you treat?
-
4:14
case based panel discussion - egfr and high pdl1 what is the role of immunotherapy in treatment?
-
6:17
case based panel discussion - stage 3 nsclc - patients with pdl1 - 0, is immunotherapy beneficial?
-
7:44
treatment for kras g12c mutated nsclc with high tumor mutational burden -case-based panel discussion
-
6:18
treating her2 exon-20 insertion nsclc with trastuzumab deruxtecan - case based panel discussion
-
6:15
treatment options for egfr nsclc - case based panel discussion
-
5:06
should pd-l1 be used as a biomarker for immunotherapy in lung cancer?
-
8:20
case based panel discussion - egfr - progression, next steps - a place for chemo & immunotherapy? v2